FDA Appears Poised To Approve First RSV Vaccines After Decades Of Roadblocks

After decades of stalled progress on a vaccine targeting respiratory syncytial virus (RSV), FDA is gearing up to make decisions on multiple vaccine candidates this year, which infectious diseases experts say could make waves for the public health community’s ability to manage respiratory viruses. FDA’s Vaccines and Related Biological Products Committee will meet Tuesday (Feb. 28) and Wednesday (March 1) to discuss and make recommendations on both Pfizer’s and GlaxoSmithKline’s RSV vaccine candidates for people 60 and older. If the...